Although CML patients on treatment with dasatinib develop increased levels of classical NK cells (CD3-CD56+) in comparison with other TKIs [20], long-term TFR is also feasible in patients treated with imatinib and nilotinib [6,21,22]. The gene discussed is NCAM1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.